Telectronics Guardian ATP2 ICD could get panel review this year, company says.
This article was originally published in The Gray Sheet
TELECTRONICS GUARDIAN ATP2 IMPLANTABLE DEFIBRILLATOR FDA PANEL REVIEW could occur later this year, the company says. Telectronics is hoping that a premarket approval application for its second-generation implantable cardioverter defibrillator will be reviewed by FDA's Circulatory System Devices Advisory Panel at a meeting scheduled for late August. The company submitted the PMA to FDA last summer.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.